SkinBioTherapeutics Reports Strong FY25 Growth and Strategic Developments

SkinBioTherapeutics plc (LSE:SBTX) provided a trading update for FY25, projecting revenues between £4.5 million and £4.8 million, reflecting strong growth from both acquisitions and organic sales. While slightly below market expectations due to the timing of certain orders, the company is approaching profitability, with a reduced EBITDA loss. A robust cash position, strengthened by a recent fundraising round, supports a commercial agreement with Superdrug to launch AxisBiotix™ supplements. Post-year-end trading has remained strong, and preparations for the Superdrug rollout are well underway, setting the stage for accelerated growth and enhanced shareholder value.

Outlook

Although SkinBioTherapeutics continues to face financial challenges with ongoing losses and cash burn, strategic partnerships and recent corporate initiatives could provide meaningful upside in the future. Current technical indicators show bearish trends, but the company’s expansion plans and commercial progress offer potential long-term benefits once translated into improved financial results.

About SkinBioTherapeutics

SkinBioTherapeutics is a life sciences company specializing in skin health, leveraging its proprietary SkinBiotix® platform, developed in collaboration with the University of Manchester’s translational dermatology team. The company targets the skin healthcare market through five key pillars, focusing on cosmetic skincare and food supplements that connect gut and skin health. Products include AxisBiotix-Ps™, a supplement aimed at inflammatory skin conditions. SkinBioTherapeutics also partners with Croda plc and is expanding through acquisitions in skincare and cosmetics, enhancing both distribution and manufacturing capabilities.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.